Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4952
Abstract: Despite the reduction in cancer recurrence and mortality provided by therapies that target the estrogen receptor (ER), resistant ER+ breast cancer remains the most common cause of breast cancer death. Beyond mutations in ER in… read more here.
Keywords: her2 mutations; resistance directed; breast cancer; resistance ... See more keywords